BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22205504)

  • 1. Prognostic significance of absolute lymphocyte count at diagnosis of diffuse large B-cell lymphoma: a meta-analysis.
    Feng J; Wang Z; Guo X; Chen Y; Cheng Y; Tang Y
    Int J Hematol; 2012 Feb; 95(2):143-8. PubMed ID: 22205504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic role of peripheral blood lymphocyte/monocyte ratio at diagnosis in diffuse large B-cell lymphoma: a meta-analysis.
    Lin B; Chen C; Qian Y; Feng J
    Leuk Lymphoma; 2015; 56(9):2563-8. PubMed ID: 25686648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma.
    Cox MC; Nofroni I; Ruco L; Amodeo R; Ferrari A; La Verde G; Cardelli P; Montefusco E; Conte E; Monarca B; Aloe-Spiriti MA
    Leuk Lymphoma; 2008 Sep; 49(9):1745-51. PubMed ID: 18798109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of prognostic impact of absolute lymphocyte count, absolute monocyte count, absolute lymphocyte count/absolute monocyte count prognostic score and ratio in patients with diffuse large B cell lymphoma.
    Markovic O; Popovic L; Marisavljevic D; Jovanovic D; Filipovic B; Stanisavljevic D; Matovina-Brko G; Hajder J; Matkovic T; Živkovic R; Stanisavljevic N; Todorović M; Petrovic D; Mihaljevic B
    Eur J Intern Med; 2014 Mar; 25(3):296-302. PubMed ID: 24565533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
    Oki Y; Yamamoto K; Kato H; Kuwatsuka Y; Taji H; Kagami Y; Morishima Y
    Eur J Haematol; 2008 Dec; 81(6):448-53. PubMed ID: 18691256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between the absolute lymphocyte count/absolute monocyte count ratio, soluble interleukin 2 receptor level, serum programmed cell death 1 level, and the prognosis of patients with diffuse large B-cell lymphoma.
    Li C; Li W; Xu G; You M; Wu W; Kuang L
    Ann Palliat Med; 2021 Oct; 10(10):10938-10945. PubMed ID: 34763456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma.
    Porrata LF; Ristow K; Habermann TM; Witzig TE; Inwards DJ; Markovic SN
    Am J Hematol; 2009 Feb; 84(2):93-7. PubMed ID: 19123458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of early recovery of peripheral blood absolute lymphocyte count after frontline autologous stem cell transplantation for diffuse large B-cell lymphoma.
    Kim Y; Kim SJ; Cheong JW; Cho H; Chung H; Lee JY; Jang JE; Min YH; Kim JS
    Hematol Oncol; 2017 Dec; 35(4):465-471. PubMed ID: 27440113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infused Autograft Absolute Lymphocyte Count Predicts Superior Survival in Diffuse Large B Cell Lymphoma Patients Post-Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation: A Matched Case-Control Study.
    Porrata LF; Burgstaler EA; Winters JL; Jacob E; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Villasboas J; Paludo J; Markovic SN
    Transplant Cell Ther; 2021 Sep; 27(9):769.e1-769.e8. PubMed ID: 34091071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era.
    Watanabe R; Tomita N; Itabashi M; Ishibashi D; Yamamoto E; Koyama S; Miyashita K; Takahashi H; Nakajima Y; Hattori Y; Motohashi K; Takasaki H; Ohshima R; Hashimoto C; Yamazaki E; Fujimaki K; Sakai R; Fujisawa S; Motomura S; Ishigatsubo Y
    Eur J Haematol; 2014 Mar; 92(3):204-10. PubMed ID: 24283206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma.
    Porrata LF; Ristow KM; Habermann TM; Witzig TE; Colgan JP; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Nowakowski G; Thompson CA; Markovic SN
    Leuk Lymphoma; 2014 Dec; 55(12):2728-38. PubMed ID: 24547705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy.
    Song MK; Chung JS; Seol YM; Kim SG; Shin HJ; Choi YJ; Cho GJ; Shin DH
    Ann Oncol; 2010 Jan; 21(1):140-4. PubMed ID: 19887468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Lymphocyte to Monocyte Ratio, Microvessel Density and HiGH CD44 Tumor Cell Expression in Non Hodgkin Lymphomas.
    Jelicic J; Balint MT; Jovanovic MP; Boricic N; Micev M; Stojsic J; Antic D; Andjelic B; Bila J; Balint B; Pavlovic S; Mihaljevic B
    Pathol Oncol Res; 2016 Jul; 22(3):567-77. PubMed ID: 26750138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The lower peripheral blood lymphocyte/monocyte ratio assessed during routine follow-up after standard first-line chemotherapy is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.
    Yan-Li L; Kang-Sheng G; Yue-Yin P; Yang J; Zhi-Min Z
    Leuk Res; 2014 Mar; 38(3):323-8. PubMed ID: 24439567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low prognostic nutritional index predicts poor outcome in diffuse large B-cell lymphoma treated with R-CHOP.
    Zhou Q; Wei Y; Huang F; Wei X; Wei Q; Hao X; Zhang Y; Feng R
    Int J Hematol; 2016 Oct; 104(4):485-90. PubMed ID: 27393279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.
    Porrata LF; Rsitow K; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Habermann TM; Witzig TE; Colgan JP; Nowakowski GS; Thompson CA; Markovic SN
    Leukemia; 2010 Jul; 24(7):1343-9. PubMed ID: 20485372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphoma.
    Porrata LF; Ristow K; Habermann TM; Ozsan N; Dogan A; Macon W; Colgan JP; Witzig TE; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Nowakowski GS; Thompson C; Markovic SN
    Leuk Lymphoma; 2012 Nov; 53(11):2159-65. PubMed ID: 22551474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with diffuse large B cell lymphoma in partial response or stable disease after first-line R-CHOP: the prognostic value of the absolute lymphocyte count and impact of autologous stem cell transplantation.
    Hung MH; Yu YB; Huang YC; Liu HT; Hong YC; Hsiao LT; Liu JH; Gau JP; Chiou TJ; Chen PM; Tzeng CH; Liu CY
    Ann Hematol; 2012 Dec; 91(12):1907-15. PubMed ID: 22885989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic impact of absolute lymphocyte and monocyte counts at diagnosis of diffuse large B-cell lymphoma in the rituximab era.
    Aoki K; Tabata S; Yonetani N; Matsushita A; Ishikawa T
    Acta Haematol; 2013; 130(4):242-6. PubMed ID: 23860478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absolute lymphocyte count at day + 21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone.
    Chae YS; Shin H; Sohn SK; Lee SJ; Moon JH; Kang BW; Kim JG; Yang DH; Lee JJ; Park TI
    Leuk Lymphoma; 2012 Sep; 53(9):1757-63. PubMed ID: 22372848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.